The peptide revolution has arrived.
What’s happening: Protocole launched with $6M in funding, including a seed round led by Rare Capital, to deliver personalized peptide protocols for longevity, performance, and metabolic health.
New standard. Emphasizing structure and safety, Protocole connects users to licensed clinicians, regulated pharmacies, and formalized treatment. More than a marketplace or one-off fulfillment, it builds complementary, outcome-driven stacks.
Gray matter. As the FDA prepares to reclassify 14 peptides for legal production, Protocole aims to legitimize an underground economy, where biohackers and wellness-seekers have turned to unregulated, often overseas sources.
Reframing peptides from fringe to clinical, longevity operators and Protocole co-founders Delphine Le Grand and Cindy Yan are creating infrastructure for responsible use.
Distinguishing multi-peptide protocols from self-directed supplements, the platform doesn’t stop at access, building trust through oversight and iteration. Resonating with beta users, demand has expanded beyond performance-focused men to women seeking integrated, daily use cases.
Looking ahead: The gray- to white-market shift is underway, with trillion-dollar implications. Leading with transparency and efficacy, Protocole is helping move peptides from IYKYK culture to standardized care.
